These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 17435765)

  • 1. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
    Cunningham D; Danley DE; Geoghegan KF; Griffor MC; Hawkins JL; Subashi TA; Varghese AH; Ammirati MJ; Culp JS; Hoth LR; Mansour MN; McGrath KM; Seddon AP; Shenolikar S; Stutzman-Engwall KJ; Warren LC; Xia D; Qiu X
    Nat Struct Mol Biol; 2007 May; 14(5):413-9. PubMed ID: 17435765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
    Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
    Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
    Fisher TS; Lo Surdo P; Pandit S; Mattu M; Santoro JC; Wisniewski D; Cummings RT; Calzetta A; Cubbon RM; Fischer PA; Tarachandani A; De Francesco R; Wright SD; Sparrow CP; Carfi A; Sitlani A
    J Biol Chem; 2007 Jul; 282(28):20502-12. PubMed ID: 17493938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
    Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
    J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).
    Palmer-Smith H; Basak A
    Curr Med Chem; 2010; 17(20):2168-82. PubMed ID: 20423303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
    Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
    Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
    Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
    Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding to the low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme.
    Geoghegan KF; Hoth LR; Varghese AH; Lin W; Boyd JG; Griffor MC
    Biochemistry; 2009 Apr; 48(13):2941-9. PubMed ID: 19222187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
    Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
    J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.
    Lo Surdo P; Bottomley MJ; Calzetta A; Settembre EC; Cirillo A; Pandit S; Ni YG; Hubbard B; Sitlani A; Carfí A
    EMBO Rep; 2011 Dec; 12(12):1300-5. PubMed ID: 22081141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for LDL receptor recognition by PCSK9.
    Kwon HJ; Lagace TA; McNutt MC; Horton JD; Deisenhofer J
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1820-5. PubMed ID: 18250299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.
    Pearlstein RA; Hu QY; Zhou J; Yowe D; Levell J; Dale B; Kaushik VK; Daniels D; Hanrahan S; Sherman W; Abel R
    Proteins; 2010 Sep; 78(12):2571-86. PubMed ID: 20589640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorting an LDL receptor with bound PCSK9 to intracellular degradation.
    Leren TP
    Atherosclerosis; 2014 Nov; 237(1):76-81. PubMed ID: 25222343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
    J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.